Trial · NCT02132468
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
NCT02132468, Phase 2, Completed, Mateon Therapeutics; results first posted 2017-10-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers. Trials, record NCT02132468. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02132468
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
- NCT number
- NCT02132468
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- Mateon Therapeutics
- Conditions
- Neuroendocrine Tumors
- Interventions
- fosbretabulin tromethamine
- First posted
- 2014-05-07
- Last updated
- 2017-12-05
- Results first posted
- 2017-10-19
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Baseline and 4 months | The mean change from baseline in chromogranin A (CgA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%. |
| Primary | Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Baseline and 4 months | The mean change from baseline in 5-hydroxyindoleacetic acid (5-HIAA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%. |
| Primary | Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Baseline and 4 months | The mean change from baseline in serotonin biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%. |
| Secondary | Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1 | Baseline and 4 months | The objective response rate (complete response, partial response, progressive disease, or stable disease) was determined by the investigator assessment of the participant's CT or MRI using Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) for target lesions. Partial Response (PR) is when there is at least 30% decrease in sum of the longest diameter of the target lesions. Progressive Disease (PD) is when there is at least 20% increase in the sum of the longest diameter of the target lesions, as well as an absolute increase of at least 5 mm (including appearance of new lesions). Stable Disease (SD) is when there neither a PR nor PD is noted. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Baseline and 4 months | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Baseline and 4 months | Participants who had 5-hydroxyindoleacetic acid (5-HIAA) biomaker sample taken at baseline and at 4 months. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Baseline and 4 months | Participants who had serotonin biomaker samples taken at baseline and at 4 months. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1 | Baseline and 4 months | Modified Intent-to-Treat | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Improved | 1 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Stable | 11 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Worsened | 6 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Improved | 2 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Stable | 8 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Worsened | 3 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Improved | 0 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Stable | 10 | Participants | |
| Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline | Fosbretabulin Tromethamine | Worsened | 2 | Participants | |
| Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1 | Fosbretabulin Tromethamine | Partial Response | 1 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Fosbretabulin Tromethamine | 18 | |
| Overall Study | COMPLETED | Fosbretabulin Tromethamine | 11 | |
| Overall Study | NOT COMPLETED | Fosbretabulin Tromethamine | 7 |
Source ClinicalTrials.gov
Adverse events116
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Fosbretabulin Tromethamine | 4 | 18 | |
| other | Leukaemoid reaction | Blood and lymphatic system disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | Leukopenia | Blood and lymphatic system disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | Palpitations | Cardiac disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | Tinnitus | Ear and labyrinth disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | Carcinoid Syndrome | Endocrine disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | Conjunctivitis Allergic | Eye disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | Macular fibrosis | Eye disorders | Fosbretabulin Tromethamine | 1 | 18 | |
| other | vision blurred | Eye disorders | Fosbretabulin Tromethamine | 1 | 18 |
1 to 10 of 116Source ClinicalTrials.gov
See all 116 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Fosbretabulin Tromethamine | 1 | 18 |
| Total, other adverse events | Fosbretabulin Tromethamine | 18 | 18 |
| Total, serious adverse events | Fosbretabulin Tromethamine | 2 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02132468
GET https://conductscience.org/api/trials/v1/NCT02132468/events?page=2